FDA advisers endorse Eli Lilly’s early-stage Alzheimer’s drug donanemab
WEBJun 11, 2024 · On Monday, a panel of independent advisers to the US Food and Drug Administration voted to endorse Eli Lilly’s drug donanemab, a monoclonal antibody designed to slow the progression of...
New Drug Approved for Early Alzheimer’s - The New York Times
WEBJul 2, 2024 · The drug, Kisunla, made by Eli Lilly, is the latest in a new class of treatments that could modestly slow cognitive decline in initial stages of the disease but also carry safety risks.
News Release - Eli Lilly and Company
WEBJul 2, 2024 · Kisunla™ (donanemab-azbt) (pronounced kih-SUHN-lah) is an amyloid-targeting treatment for people with mild cognitive impairment (MCI) as well as people with mild dementia stage of early symptomatic Alzheimer's …
Experimental Alzheimer's drug donanemab outperforms Leqembi in ... - NPR
WEBJul 17, 2023 · In a large study, the experimental drug donanemab slowed the progression of Alzheimer's by about 35%. That's slightly better than the drug Leqembi, which was fully approved by the FDA on July 6.
FDA Approves Kisunla (Donanemab) | Alzheimer's Association
WEBCHICAGO, July 2, 2024 — The Alzheimer’s Association celebrates today’s U.S. Food and Drug Administration (FDA) action to approve Kisunla™ (donanemab, Eli Lilly) for the treatment of people living with early symptomatic Alzheimer’s disease, which includes mild cognitive impairment and the mild dementia stage of Alzheimer’s disease ...
News Release - Eli Lilly and Company
WEBMay 3, 2023 · Donanemab treatment slowed clinical decline by 35% compared to placebo, and resulted in 40% less decline on the ability to perform activities of daily living. Over half of all participants completed their course of treatment by 12 months
FDA Advisory Committee Agrees on Donanemab Efficacy | alz.org
WEBJun 10, 2024 · The Alzheimer’s Association welcomes the advisory committee’s unanimous finding that donanemab is effective for the treatment of early Alzheimer’s disease. If approval is granted by the FDA, donanemab will be the second traditional approval of an Alzheimer’s treatment to change the underlying course of the disease.
Eli Lilly expects FDA decision on Alzheimer’s treatment donanemab …
WEBJul 17, 2023 · An FDA approval of Eli Lilly’s donanemab would expand the treatment options for the more than 6 million Americans of all ages who have Alzheimer’s, the fifth-leading cause of death for...
Alzheimer’s drug donanemab: what promising trial means for
WEBMay 4, 2023 · On 3 May, pharmaceutical company Eli Lilly announced in a press release that its monoclonal antibody donanemab slowed mental decline by 35% for some participants in a 1,736-person trial — a rate...
Drug donanemab seen as turning point in dementia fight - BBC News
WEBJul 17, 2023 · A new drug, donanemab, is being hailed as a turning point in the fight against Alzheimer's, after a global trial confirms it slows cognitive decline. The antibody medicine helps in the early...